Skip to main content

Hatteras Venture Partners — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

63
Companies
$2.0B
Total invested
$35.7M
Avg. check
21
Industries
Health Care 16Biotechnology 14Therapeutics 11Medical 8Medical Device 8Life Science 6+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 63
Sensorium Therapeutics
August 2025

Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines.

Health Care · Boston$25.0M Series A
Boston Immune Technologies & Therapeutics
August 2024

This company is a Boston-based biopharmaceutical company developing immune-based approaches.

Biotechnology · Winchester$4.0M Grant
RapidPulse
July 2026

RapidPulse is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke

Health Care · Miami$48.0M Series B
Clearside Biomedical
July 2026

Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.

Biotechnology · Alpharetta$3.0M Post-IPO Debt
410 Medical
July 2026

410 Medical is a medical device company dedicated to developing innovative products that enable frontline medical providers to improve care.

Health Care · Durham$12.0M Venture - Series Unknown
Code Biotherapeutics
June 2022

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.

Biotechnology · Hatfield$75.0M Series A
Vigil Neuroscience
June 2024

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.

Biotechnology · Cambridge$40.0M Post-IPO Equity
Ladder Health
June 2026

Ladder Health offers virtual pediatric therapy and support for early childhood developmental delays, including speech and physical therapy.

Child Care · New York$7.0M Seed
Veralox Therapeutics
June 2023

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.

Biotechnology · Frederick$24.0M Venture - Series Unknown
GoCheck
June 2025

GoCheck, creator of GoCheck Kids, helps primary care networks implement pediatric vision screening.

Health Care · Nashville$3.5M Undisclosed
Shattuck Labs
June 2026

Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.

Biopharma · Austin$75.0M Post-IPO Equity
Standard Bariatrics
May 2022

Standard Bariatrics is a medical device company that develops and offers surgical instruments for weight-loss surgeries.

Health Care · Cincinnati$7.0M Debt Financing
CREATE Medicines
May 2026

CREATE Medicines is a biotech company developing in vivo CAR therapies using mRNA-LNP immune cell programming technology.

Biotechnology · Cambridge$122.0M Series B
Incyclix Bio
April 2026

Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.

Biotechnology · Durham$5.0M Series B
Altis Biosystems
April 2025

Altis Biosystems is a biotechnology company developing research tools for the pharma and biotech industries.

Biotechnology · Durham$2.1M Venture - Series Unknown
iVEAcare
April 2024

iVEAcare develops innovative neuromodulation therapy to treat unmet clinical needs.

Health Care · Minneapolis$27.5M Series A
Pharaoh Neuro
February 2026

Pharaoh Neuro develops a neurapheresis cerebrospinal fluid management system for neurological patients.

Manufacturing · Minneapolis$20.0M Series A
Boomerang Medical
September 2025

Boomerang Medical is a bioelectronic medical enterprise.

Biotechnology · Mountain View$20.0M Series B
Mercy BioAnalytics
September 2025

Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.

Biotechnology · Natick$59.0M Series B
GeneCentric Therapeutics
June 2025

GeneCentric Therapeutics develops and commercializes molecular diagnostic tests for oncologists and patients.

Biotechnology · Durham$8.0M Series C
Trefoil Therapeutics
May 2025

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.

Biotechnology · San Diego$4.6M Venture - Series Unknown
Huma.AI
April 2025

Huma is a provider of business intelligence platform built to automate healthcare through human language.

Artificial Intelligence (AI) · Cary$1.0M Venture - Series Unknown
Atsena Therapeutics
April 2025

Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.

Biotechnology · Durham$150.0M Series C
BEKHealth
February 2025

BEKhealth harnesses its AI-powered chart abstraction and patient-matching platform to optimize clinical research enrollment.

Clinical Trials · Branford$4.0M Venture - Series Unknown

Where Hatteras Venture Partners invests

Health Care16
Biotechnology14
Therapeutics11
Medical8
Medical Device8
Life Science6

About Hatteras Venture Partners's portfolio

How many companies has Hatteras Venture Partners invested in?

Hatteras Venture Partners has invested in 63 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Hatteras Venture Partners invest in?

Hatteras Venture Partners's top investment sectors include Health Care, Biotechnology, Therapeutics, Medical, Medical Device. The firm invests across 21 different industry categories.

What is Hatteras Venture Partners's largest investment?

Among tracked funding rounds, Atsena Therapeutics received $150.0M in a Series C round. Hatteras Venture Partners's total known invested capital is $2.0B.

What is the average investment size for Hatteras Venture Partners?

Hatteras Venture Partners's average investment size is $35.7M across its portfolio of 63 companies.

What are Hatteras Venture Partners's most recent investments?

Recent Hatteras Venture Partners portfolio additions include Sensorium Therapeutics, Boston Immune Technologies & Therapeutics, RapidPulse, Clearside Biomedical, 410 Medical. These companies were founded in 2020 or later.

Reach the founders behind these 63 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →